宜明昂科与Instil Bio就IMM2510和IMM27M达成许可协议

ImmuneOnco Biopharmaceuticals and Instil Bio announced a licensing agreement for IMM2510, a novel bispecific antibody targeting PD-L1 and VEGF, and IMM27M, an anti-CTLA-4 antibody.